Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of sanggenone D in preparation of medicine or pharmaceutical composition for treating hyperlipidemia and/or obesity

A technology of sanggenone and hyperlipidemia, which is applied in the field of biomedicine, can solve the problems of unreported inhibitory effect of pancreatic lipase, etc., and achieve the effect of cheap raw materials, simple and feasible process, and good safety

Inactive Publication Date: 2018-10-26
大连天星本草生物科技有限公司
View PDF7 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] However, the inhibitory effect of sanggenone D on pancreatic lipase has not been reported, nor has there been any report on the use of sanggenone D to treat hyperlipidemia and obesity.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of sanggenone D in preparation of medicine or pharmaceutical composition for treating hyperlipidemia and/or obesity
  • Application of sanggenone D in preparation of medicine or pharmaceutical composition for treating hyperlipidemia and/or obesity
  • Application of sanggenone D in preparation of medicine or pharmaceutical composition for treating hyperlipidemia and/or obesity

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0043] The present embodiment prepares Sanggenone D tablet

[0044] Accurately weigh 20 g of Sanggen D monomer (purity greater than 98%), add 180 g of medicinal starch, and mix the two thoroughly to make 400 tablets, each weighing 0.5 g, containing 50 mg of Sanggen D.

Embodiment 2

[0046] The present embodiment prepares Sanggenone D capsule

[0047] Accurately weigh 20g of Sanggenone D monomer (purity greater than 98%), add 180g of medicinal starch, mix the two fully and use a 20-mesh sieve to make granules, then subpackage and fill them into hollow capsules, and subpackage into 400 cases Capsules, each capsule weighs 0.5g, containing 50mg of sanggenone D.

Embodiment 3

[0049] IC of Pancreatic Lipase Inhibition by Sanggenone D 50 determination

[0050] Taking the hydrolytic metabolism of 4-methylumbelliferone oleate as a probe reaction, and using the in vitro incubation system of pancreatic lipase, the IC of the inhibition of sanggenone D on pancreatic lipase was determined 50 , the result is as figure 1 Shown; Simultaneously, draw the time-dependent inhibition curve of Pancrelipase by Sanggenone D, such as figure 2 shown.

[0051] a. In 200 microliters of in vitro metabolic reaction system, containing 0.1M phosphate buffer solution with pH 7.4, the concentration of pancreatic lipase is 2 μg / mL, and the final concentration of inhibitor is in the range of 0.1 μM-50 μM. Incubation for 5min, 10min, 25min;

[0052] b. Add the substrate (final concentration 10 μM) to the 96-well plate, then add the pre-incubation solution to the 96-well plate to start the reaction; continuously detect the metabolic hydrolyzate in a multifunctional microplate ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides application of sanggenone D in preparation of a medicine or pharmaceutical composition for treating hyperlipidemia and / or obesity. The invention develops a novel strategy for preparing medicines for treating hyperlipidemia and / or obesity, namely a medicine for treating hyperlipidemia and / or obesity prepared from sanggenone D, monomeric compounds of sanggenone D, or plant extract or dietary supplement containing the compounds. Digestion and absorption of dietary fat can be further reduced by strongly inhibiting pancrelipase, the effects of reducing blood fat and losing weight are achieved, and the IC50 of the sanggenone D inhibiting pancrelipase can reach 0.77micron. In addition, due to combined use of the sanggenone D and other drugs or natural products, the drug effects are further achieved, and the sanggenone D has wide application prospects and a huge market value.

Description

technical field [0001] The invention belongs to the field of biomedicine, and relates to a new application of sanggenone D, in particular to an application of sanggenone D in preparing a medicine or a pharmaceutical composition for treating hyperlipidemia and / or obesity. Background technique [0002] Due to modern lifestyles and the increase in high-fat diets, obesity has become a global problem that has attracted widespread attention. Obesity is the result of a chronic imbalance between energy intake and energy expenditure, and obesity is an important contributor to a variety of metabolic diseases, such as hyperlipidemia, hypertension, arteriosclerosis, non-insulin-dependent diabetes mellitus, coronary heart disease, and certain types of cancer. Therefore, it is very necessary to discover and prepare drugs for reducing blood fat and weight loss, and one of the important targets is to reduce the digestion and absorption of fat in digestive organs. Pancreatic lipase (also kn...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P3/04A61P3/06A23L33/105
CPCA23V2002/00A61K31/352A23L33/105A61P3/04A61P3/06A23V2200/332A23V2250/21
Inventor 侯洁刘磊葛广波侯旭东
Owner 大连天星本草生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com